Mesalazin Orion (Mesalazine)

Mesalazine works locally in the gastrointestinal tract. It blocks cyclooxygenase and lipoxygenase enzymes, which decreases the production of prostaglandins and leukotrienes—key mediators of inflammation. This action helps calm the immune response in the colon and rectal mucosa.

The dose of Mesalazin Orion is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the patient’s condition, severity, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances and monitor closely if therapy is continued.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesalazin Orion delivers mesalazine directly to the colon via a rectal formulation, offering targeted therapy with potentially fewer systemic effects compared with oral 5‑ASA agents such as sulfasalazine. It may be preferred for distal disease (proctitis) or when oral therapy is insufficient, but choice depends on disease extent, patient preference, and physician judgment.

Mesalazin Orion should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Mesalazin Orion is administered rectally. The prescribed dose is typically introduced into the rectum using an applicator or enema bottle, allowing the medication to coat the mucosal surface of the distal colon and rectum. Patients should follow the specific instructions provided by their healthcare professional.

Serious adverse events, although rare, include severe hypersensitivity reactions (rash, fever, eosinophilia), hepatotoxicity (significant liver enzyme elevation), and nephrotoxicity (decline in kidney function). Prompt medical evaluation is required if any of these symptoms develop.

Mesalazin Orion is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those taking drugs that may cause additive toxicity without appropriate monitoring.